AstraZeneca’s (AZN) “Hold” Rating Reaffirmed at Deutsche Bank Aktiengesellschaft

AstraZeneca (LON:AZN)‘s stock had its “hold” rating reissued by investment analysts at Deutsche Bank Aktiengesellschaft in a note issued to investors on Tuesday, September 29th, Digital Look reports. They currently have a £117 price objective on the biopharmaceutical company’s stock. Deutsche Bank Aktiengesellschaft’s price objective indicates a potential downside of 2.97% from the company’s previous close.

AZN has been the topic of a number of other research reports. Citigroup boosted their target price on shares of AstraZeneca from £175 to £178 and gave the stock a “buy” rating in a research report on Tuesday, July 28th. Berenberg Bank reduced their price target on shares of AstraZeneca from £160 to £150 and set a “buy” rating for the company in a report on Tuesday, September 15th. Jefferies Financial Group restated a “buy” rating and issued a £175 price target on shares of AstraZeneca in a research report on Wednesday, September 9th. Finally, Royal Bank Of Canada restated an “outperform” rating and set a £145 price objective on shares of AstraZeneca in a report on Tuesday, September 8th. Six research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, AstraZeneca has an average rating of “Moderate Buy” and a consensus price target of £150.

AstraZeneca Stock Up 2.5%

Shares of AZN stock opened at £120.58 on Tuesday. AstraZeneca has a 12 month low of £114.04 and a 12 month high of £157.32. The company has a quick ratio of 0.59, a current ratio of 0.89 and a debt-to-equity ratio of 64.10. The firm has a market cap of £187.01 billion, a PE ratio of 18.05, a price-to-earnings-growth ratio of 0.86 and a beta of 0.20. The stock has a 50 day moving average of £121.13 and a 200-day moving average of £132.49.

Insider Buying and Selling at AstraZeneca

In other news, insider Michel Demare acquired 2,500 shares of the stock in a transaction dated Monday, September 14th. The shares were acquired at an average cost of £121.21 per share, for a total transaction of £303,025. Insiders own 0.15% of the company’s stock.

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.